Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

Eriksson, C., Söderling, J., Karlqvist, S., Bröms, G., Everhov, Å. H., Bergemalm, D., Ludvigsson, J. F., Olén, O., & Halfvarson, J. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn’s Disease. Digestive Diseases and Sciences, 68(7), 3119–3128. https://doi.org/10.1007/s10620-023-07897-2
Authors:
Carl Eriksson
Jonas Söderling
Sara Karlqvist
Gabriella Bröms
Åsa H Everhov
Daniel Bergemalm
Jonas F Ludvigsson
Ola Olén
Jonas Halfvarson
Affiliated Authors:
Jonas F Ludvigsson
Columbia Affiliation:
Subjects:
Crohn Disease (MeSH)
Biological Products (MeSH)
Author Keywords:
anti-tnf
comparative effectiveness
comparative safety
crohn’s disease
population-based study
ustekinumab
elink
Publication Type:
Article
Unique ID:
10.1007/s10620-023-07897-2
PMID:
36929241
DOI:
10.1007/s10620-023-07897-2
Journal:
Digestive Diseases and Sciences
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: